Coronavirus disease 2019: What we know?

Feng He, Yu Deng, Weina Li, Feng He, Yu Deng, Weina Li

Abstract

In late December 2019, a cluster of unexplained pneumonia cases has been reported in Wuhan, China. A few days later, the causative agent of this mysterious pneumonia was identified as a novel coronavirus. This causative virus has been temporarily named as severe acute respiratory syndrome coronavirus 2 and the relevant infected disease has been named as coronavirus disease 2019 (COVID-19) by the World Health Organization, respectively. The COVID-19 epidemic is spreading in China and all over the world now. The purpose of this review is primarily to review the pathogen, clinical features, diagnosis, and treatment of COVID-19, but also to comment briefly on the epidemiology and pathology based on the current evidence.

Keywords: COVID-19; SARS-CoV-2; coronavirus.

Conflict of interest statement

The authors declare that there are no conflict of interests.

© 2020 The Authors. Journal of Medical Virology published by Wiley Periodicals Inc.

Figures

Figure 1
Figure 1
Schematic model of SARS‐CoV‐2 life cycle. S protein binds to the cellular receptor ACE2 to facilitate the entry of the virus. After the fusion of viral and plasma membranes, virus RNA undergoes replication and transcription. The proteins are synthesized. Viral proteins and new RNA genome are subsequently assembled in the ER and Golgi, followed by budding into the lumen of the ERGIC. New virions are released through vesicles. ACE2, angiotensin‐converting enzyme 2; ER, endoplasmic reticulum; ERGIC, endoplasmic reticulum‐Golgi intermediate compartment
Figure 2
Figure 2
Chest CT Manifestations of COVID‐19. A, Single GGO; B, diffuse GGO; C, consolidation; D, both GGO and consolidation. COVID‐19, coronavirus disease 2019; CT, computed tomography; GGO, ground‐glass opacities
Figure 3
Figure 3
Mortality rates of different countries or regions, 27 February 2020. *A cruise ship currently in Japanese territorial waters

References

    1. Wuhan Municipal Health Commission . Report of Clustering Pneumonia of Unknown Etiology in Wuhan City. 2019. . Accessed December 31, 2019.
    1. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565‐574.
    1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270‐273.
    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727‐733.
    1. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327‐347.
    1. Chan JF, Lau SK, Woo PC. The emerging novel Middle East respiratory syndrome coronavirus: the “knowns” and “unknowns”. J Formos Med Assoc. 2013;112(7):372‐381.
    1. Channappanavar R, Zhao J, Perlman S. T cell‐mediated immune response to respiratory coronaviruses. Immunol Res. 2014;59(1‐3):118‐128.
    1. Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007;20(4):660‐694.
    1. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS‐like disease. Clin Microbiol Rev. 2015;28(2):465‐522.
    1. Gretebeck LM, Subbarao K. Animal models for SARS and MERS coronaviruses. Curr Opin Virol. 2015;13:123‐129.
    1. Gralinski LE, Baric RS. Molecular pathology of emerging coronavirus infections. J Pathol. 2015;235(2):185‐195.
    1. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967‐1976.
    1. Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV. J Med Virol. 2020;92(5):491‐494. 10.1002/jmv.25709
    1. Zhou P, Yang X‐L, Wang X‐G, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv. 2020. 10.1101/2020.01.22.914952. [published online ahead of print January 2020].
    1. Li X, Zai J, Zhao Q, et al. Evolutionary history, potential intermediate animal host, and cross‐species analyses of SARS‐CoV‐2. J Med Virol. 2020. 10.1002/jmv.25731. [published online ahead of print February 27, 2020].
    1. Li W, Moore MJ, Vasilieva N, et al. Angiotensin‐converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450‐454.
    1. Wang Q, Wong G, Lu G, Yan J, Gao GF. MERS‐CoV spike protein: targets for vaccines and therapeutics. Antiviral Res. 2016;133:165‐177.
    1. Wrapp D, Wang N, Corbett KS, et al. Cryo‐EM structure of the 2019‐nCoV spike in the prefusion conformation. Science. 2020;367:1260‐1263.
    1. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS‐CoV–a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226‐236.
    1. Lu G, Wang Q, Gao GF. Bat‐to‐human: spike features determining 'host jump' of coronaviruses SARS‐CoV, MERS‐CoV, and beyond. Trends Microbiol. 2015;23(8):468‐478.
    1. Li F. Structure, function, and evolution of coronavirus spike. Proteins. Annu Rev Virol. 2016;3(1):237‐261.
    1. He Y, Zhou Y, Liu S, et al. Receptor‐binding domain of SARS‐CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004;324(2):773‐781.
    1. Oudit GY, Kassiri Z, Jiang C, et al. SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39(7):618‐625.
    1. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus‐induced lung injury. Nat Med. 2005;11(8):875‐879.
    1. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus‐infected pneumonia. N Engl J Med. 2020. 10.1056/NEJMoa2001316. [published online ahead of print January 29, 2020].
    1. Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person‐to‐person transmission: a study of a family cluster. Lancet. 2020;395(10223):514‐523.
    1. Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS‐CoV‐2 infection. J Med Virol. 2020. 10.1002/jmv.25725. [published online ahead of print February 26, 2020].
    1. Loon SC. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol. 2004;88(7):861‐863.
    1. Zhao S, Lin Q, Ran J, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019‐nCoV) in China, from 2019 to 2020: a data‐driven analysis in the early phase of the outbreak. Int J Infect Dis. 2020;92:214‐217.
    1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‐infected pneumonia in Wuhan, China. JAMA. 2020. 10.1001/jama.2020.1585. [published online ahead of print February 7, 2020].
    1. Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID‐19. JAMA. 2020. 10.1001/jama.2020.2565. [published online ahead of print February 21, 2020].
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020. 10.1001/jama.2020.2648. [published online ahead of print February 24, 2020].
    1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507‐513.
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497‐506.
    1. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT‐PCR testing in coronavirus disease 2019 (COVID‐19) in China: a report of 1014 Cases. Radiology. 2020. 10.1148/radiol.2020200642. [published online ahead of print February 26, 2020].
    1. Pan F, Ye T, Sun P, et al. Time course of lung changes on chest ct during recovery from 2019 novel coronavirus (COVID‐19) pneumonia. Radiology. 2020. 10.1148/radiol.2020200370. [published online ahead of print February 13, 2020].
    1. Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019‐nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020. 10.1007/s00330-020-06731-x. [published online ahead of print February 13, 2020].
    1. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID‐19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020. 10.1016/S1473-3099(20)30086-4. [published online ahead of print February 24, 2020].
    1. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID‐19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020. 10.1016/S2213-2600(20)30076-X. [published online ahead of print February 18, 2020].
    1. Hui DSC, Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin North Am. 2019;33(4):869‐889.
    1. van den Brand JM, Smits SL, Haagmans BL. Pathogenesis of Middle East respiratory syndrome coronavirus. J Pathol. 2015;235(2):175‐184.
    1. Nassar MS, Bakhrebah MA, Meo SA, Alsuabeyl MS, Zaher WA. Middle east respiratory syndrome coronavirus (MERS‐CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci. 2018;22(15):4956‐4961.
    1. Binnicker MJ. Emergence of a novel coronavirus disease (COVID‐19) and the importance of diagnostic testing: why partnership between clinical laboratories, public health agencies, and industry is essential to control the outbreak. Clin Chem. 2020. 10.1093/clinchem/hvaa071. [published online ahead of print March 12, 2020].
    1. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019‐nCoV) by real‐time RT‐PCR. Euro Surveill. 2020;25(3):2000045.
    1. Zou L, Ruan F, Huang M, et al. SARS‐CoV‐2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020. 10.1056/NEJMc2001737. [published online ahead of print March 19, 2020].
    1. Yang Y, Yang M, Shen C, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019‐nCoV infections. MedRxiv. 2020. 10.1101/2020.02.11.20021493. [published online ahead of print February 17, 2020].
    1. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929‐936.
    1. Arabi YM, Mandourah Y, Al‐Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757‐767.
    1. Lansbury L, Rodrigo C, Leonardi‐Bee J, Nguyen‐Van‐Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019;2(2):CD010406. 10.1002/14651858.CD010406
    1. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.
    1. Khamitov RA, Loginova S, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol. 2008;53(4):9‐13.
    1. Luo H, Tang Q, Shang Y, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID‐19)? a review of historical classics, research evidence and current prevention programs. Chin J Integr Med. 2020. 10.1007/s11655-020-3192-6. [published online ahead of print February 17, 2020].
    1. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441‐447.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다